82 results about "Transdermal patch" patented technology

The present invention provides a novel method for manufacturing a microstructure via the use of a viscous polymer, particularly microstructures that may be found on medical devices, such as transdermal patches, for either cosmetic or medicinal purposes.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a "morsel track" for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

The invention discloses a preparation method of a dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch, which comprises the following steps: uniformly mixing basic components of PDMS (Polydimethylsiloxane) with a curing agent to obtain a solution A; adding an organic solvent to obtain a solution B; adding ultrapure water to form a PDMS emulsion; pouring the PDMS emulsion on a mold, and heating and curing to obtain a PDMS sponge mold; performing static culture on the PDMS sponge mold on the bacterial liquid to obtain the bacterial cellulose hydrogel transdermal patch; putting the bacterial cellulose hydrogel transdermal patch into a NaOH solution, boiling, cooling to room temperature, and replacing the NaOH solution with deionized water until the pH is neutral, so as to obtain the dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch. According to the preparation method disclosed by the invention, the individualized dumbbell array storage type hollow bacterial cellulose hydrogel transdermal patch is synthesized through self-assembly of a PDMS sponge mold mediated bacterial interface, and the transdermal patch can be used for efficiently carrying drugs, slowly releasing for a long time and conformally attaching and is excellent in air permeability.

This invention belongs to the field of patch technology and relates to a sleep-aiding and hypnotic transdermal patch and its preparation method. The sleep-aiding and hypnotic transdermal patch includes a drug-loaded layer, which, by weight, comprises 2-9 parts of active drug and 0.1-7 parts of a penetration enhancer. The penetration enhancer is a combination of menthol and essential oil; the weight ratio of menthol to essential oil is 1-4:0.1-3. This invention, through optimizing the formulation and preparation process, successfully prepares a sleep-aiding and hypnotic transdermal patch with good permeability and stability, enabling slow release and absorption of the drug, solving the problems of insomnia and poor sleep quality; and reducing the probability of side effects while improving the therapeutic effect.

The invention belongs to the technical field of transdermal patches, and relates to a transdermal patch for improving the bioavailability of estradiol and a preparation method of the transdermal patch. The transdermal patch is prepared from the following components in percentage by weight: 5 to 21 percent of estradiol, 8 to 15 percent of polymer matrix, 0.5 to 1.5 percent of butylated hydroxytoluene, 10 to 15 percent of hydrogenated rosin glyceride, 2 to 5 percent of penetration enhancer, 3 to 8 percent of plasticizer and 25 to 35 percent of solvent. According to the transdermal patch disclosed by the invention, continuous and stable release of a medicine is realized, the transdermal absorption rate of estradiol is improved, so that the bioavailability is improved, the treatment effect is further improved, and meanwhile, the transdermal patch disclosed by the invention can also avoid a first-pass effect of the liver and reduce side effects; the transdermal drug delivery system is convenient to use, and the compliance of a patient is improved.

The invention discloses a transdermal patch containing lidocaine, the transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises active ingredients lidocaine, an acrylic acid pressure-sensitive adhesive and a penetration enhancer, the weight content of the lidocaine is 21-33%, the weight content of the acrylic acid pressure-sensitive adhesive is 45-75%, the weight content of the penetration enhancer is 1-10%, and the weight content of the penetration enhancer is 1-10%. The weight content of the penetration enhancer is 3%-25%. The transdermal patch disclosed by the invention is simple in prescription and process, good in drug permeability and colloid application performance and high in stability, can be continuously used for a long time without causing skin irritation, and is suitable for treating peripheral nerve related pains, especially patients requiring long-term administration such as post-herpes zoster neuralgia.

1. The name of the design product: transdermal patch (ion transdermal patch two). 2. The use of the design product: for protecting skin wounds. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: front view. 5. Other circumstances that need to be explained: the design product is a thin product, and the left view, right view, top view and bottom view are omitted.

The invention relates to an ibuprofen-containing transdermal patch as well as a preparation method and application thereof. The ibuprofen-containing transdermal patch comprises a polymer matrix layer, the polymer matrix layer comprises ibuprofen, a compound at least containing one amino group and a pressure-sensitive adhesive, and based on the weight of the polymer matrix layer, the ibuprofen accounts for 10-30% by weight, the compound at least containing one amino group accounts for 0.1-5% by weight, and the pressure-sensitive adhesive accounts for 0.1-5% by weight. The weight content of the pressure-sensitive adhesive is 45%-84%, the pressure-sensitive adhesive is composed of a silicone pressure-sensitive adhesive and an acrylate pressure-sensitive adhesive, and the weight ratio of the silicone pressure-sensitive adhesive to the acrylate pressure-sensitive adhesive is 1: 1-15: 1. According to the transdermal patch, the penetration capacity of ibuprofen is remarkably improved, particularly, the early-stage medicine penetration rate is higher, the medicine utilization rate is greatly improved, meanwhile, the patch is good in application performance, free of skin irritation, free of crystallization in the long-term storage process, good in stability and capable of better meeting the clinical medication requirement.

The application discloses a transdermal patch special for children with dwarfism, and relates to the technical field of medical treatment, which comprises a patch main body and a needle cylinder, and a fixed plate is fixedly connected to the inside of the patch main body, and the top and the bottom of the fixed plate are penetrated by the needle cylinder; the top of the needle cylinder is provided with a pressing plate, the bottom of the pressing plate is provided with a stand column on the two sides of the needle cylinder, the bottom of the two stand columns is arranged in the inside of the fixed plate and is slidably connected with the fixed plate; the two stand columns are both sleeved with a spring one; the top of the pressing plate is provided with a clamping groove, the bottom of the clamping groove is communicated with the needle cylinder, and a clamping seat is arranged in the clamping groove; the top of the pressing plate is provided with a fence; the two sides of the pressing plate are both provided with a connecting rod, one end of the connecting rod is connected with the pressing plate, and the other end penetrates through the top of the patch main body; the two sides of the patch main body close to the bottom are both provided with a sticking layer; and the two sides of the inside of the patch main body are both provided with a negative pressure sponge layer. The burden of the children with dwarfism is relieved, growth hormone injection treatment is facilitated, and the skin redness and swelling caused after growth hormone injection can be effectively prevented and treated.

The invention discloses an immunosuppressant transdermal patch and a preparation method thereof, the transdermal patch is provided with a backing layer, an ointment-containing body and a protective layer, the backing layer is a polyester and ethylene-vinyl acetate copolymer film, the ointment-containing body is formed by mixing a main drug tacrolimus, a stabilizer, a matrix, a cross-linking agent and a pressure-sensitive adhesive, and the protective layer is a polyester and ethylene-vinyl acetate copolymer film. The protective layer is a polyethylene glycol terephthalate film, the protective layer is coated with the ointment-containing body, and then the backing layer is pressed and covered on the surface of the ointment-containing body. The immunosuppressant transdermal patch provided by the invention can be adhered to parts such as neck, shoulder, chest, arm memory and the like, can be freely adjusted in use duration according to different illness states, and is safe and free of toxic and side effects. In addition, the transdermal patch disclosed by the invention is good in stickiness, good in permeability, free of irritation and allergy phenomena, good in patient compliance and capable of being used for a long time. Meanwhile, the method has the advantages of low preparation cost, simple and reasonable preparation process and the like, and has wide application prospects.

A transdermal patch is provided, which comprises: a backing layer; a first drug-containing adhesive layer comprising a first nicotine or a pharmaceutically acceptable salt thereof and a first adhesive; a second drug-containing adhesive layer comprising a second nicotine or a pharmaceutically acceptable salt thereof and a second adhesive; and a release liner, wherein the first drug-containing adhesive layer and the second drug-containing adhesive layer is disposed between the backing layer and the release liner.

The present application relates to the field of medicine biology, and particularly relates to a transdermal patch containing dexmedetomidine. By adding a penetration enhancer, the transdermal rate and the permeation amount are improved, the onset time is shortened, the patch content is reduced, the skin residue is reduced, and the skin redness / scarring at the administration site caused by the accumulation of the drug in the skin is effectively avoided.

The invention relates to a transdermal patch combined with an electronic control system in the form of a smartwatch. The patch features a display that shows information about the current status and drug delivery. Simultaneously, electrical contacts within the patch enable the targeted delivery of active ingredients under the skin. The system reacts in real time to the patient's condition and can be used for various applications including insulin control, blood measurement and vacuum blood tests. The invention offers precise and needs-based control of drug delivery and enables continuous monitoring and adjustment based on the patient's current needs.

The application discloses a sustained-release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations. The patch is a five-layer composite structure, and the key lies in that: the adhesive layer and the drug depot layer both contain ion pairs of clonidine and organic acid formed in situ under specific solvent and temperature conditions, and the formation of the ion pairs is confirmed by pH value or infrared spectrum; and specific transdermal penetration enhancers are further compounded, so that programmed controlled release is realized through the cooperation of the two layers. The preparation process adopts the sequence of forming ion pairs first and then mixing, realizes coating precision of ±2μm through slit extrusion coating combined with online thickness measurement closed-loop control, adopts gradient drying process with clear temperature zone, air speed and humidity parameters, and carries out real-time quality control based on the online near-infrared spectrum detection of the pre-established PLS regression model. The process can ensure that the patch realizes near-zero-order constant-speed release within 168h, and has the advantages of stable drug release, uniform content, stable quality and high batch consistency.

A transdermal patch for delivering lidocaine for pain relief comprises a backing layer, an adhesive layer, and a composition containing lidocaine in an amount ranging from about 1% to about 10% by weight and heparin as a non-anticoagulant permeation enhancer in an amount ranging from about 1% to about 50% by weight. The heparin enhances permeation of lidocaine through the skin without exerting systemic anticoagulant effects by temporarily disrupting lipid bilayers in the stratum corneum to create microchannels for increased diffusion of lidocaine molecules. The patch provides effective relief for multiple pain types including neuropathic pain, inflammatory pain, ischemic pain, post-surgical pain, nociplastic pain, mechanical pain, and compressive pain. The transdermal patch is configured to provide sustained release of lidocaine for periods ranging from about 8 hours to about 24 hours, reducing pain by at least 50% with minimal systemic absorption.

The invention discloses a cinacalcet-containing transdermal patch as well as a preparation method and application thereof. The transdermal patch comprises a high-molecular matrix layer, wherein the high-molecular matrix layer comprises cinacalcet, a silicone pressure-sensitive adhesive and one or more high-molecular polymers selected from a water-insoluble cellulose derivative, polyvinylpyrrolidone and a polyethylene caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. The transdermal patch disclosed by the invention is good in drug permeability and colloid application performance, high in safety, free of skin irritation, high in stability and good in uniformity, and can meet the requirements of clinically treating hyperparathyroidism or hypercalcemia.

This invention belongs to the field of pharmaceutical formulation technology, specifically disclosing a gastrodin transdermal patch and its preparation method. The patch consists of a backing layer, a drug-containing matrix layer, and an anti-adhesive layer, using gastrodin as the active ingredient. It employs HP-β-CD inclusion technology, combined with an HPMC and PVP polymer backbone and an oleic acid-menthol composite transdermal enhancement system. The preparation utilizes solvent casting and low-temperature vacuum drying processes, which are mild and controllable. This invention effectively solves the problems of difficult transdermal absorption, easy recrystallization, and low bioavailability of gastrodin. The resulting patch has excellent adhesion, no skin irritation, high transdermal penetration, and good skin biocompatibility. It can efficiently cross the blood-brain barrier, regulate the neuroinflammatory microenvironment in the brain, significantly inhibit the colonization and progression of non-small cell lung cancer brain metastases, and strongly reverse tumor-related anxiety and depression-like mood disorders. It provides a novel drug delivery regimen with great clinical translational potential for the non-invasive synergistic treatment of brain tumors and their associated mood disorders.

The present application relates to a transdermal patch containing colchicine and a preparation method and use thereof. The transdermal patch comprises a matrix layer, wherein the matrix layer comprises an active ingredient colchicine, a hot melt pressure sensitive adhesive and optionally other pharmaceutically acceptable adjuvants, wherein the content of the colchicine is 0.1% to 5%, the content of the hot melt pressure sensitive adhesive is 1.9% to 99.9%, and the content of the other pharmaceutically acceptable adjuvants is 0% to 98% based on the total weight of the matrix layer. The transdermal patch containing colchicine of the present application has no local irritation during and after application, no gastrointestinal side effects, high patient compliance, strong drug permeability, good therapeutic effect, and can be used for preventing and / or treating gout and / or pericarditis.

1. The name of the design product: packaging box (transdermal patch). 2. The use of the design product: packaging for transdermal patch. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The utility model discloses a coating machine for transdermal patch production, which comprises a working table, a scraper frame is arranged on the upper surface of the working table, guide holes are symmetrically formed in the upper surface of the scraper frame, a guide rod I is connected in the guide holes in a sliding manner, an electric telescopic rod I is arranged on the upper surface of the scraper frame, and a mounting frame is arranged at the output end of the electric telescopic rod I; a first rotating block and a second rotating block are rotationally connected to the two opposite surfaces of the inner wall of the mounting frame correspondingly, and a connecting plate is arranged between the first rotating block and the second rotating block. The angle of the scraper can be adjusted in real time through accurate transmission of the servo motor, the worm gear and the worm; a first electric telescopic rod is combined with a first guide rod, stability of height adjustment of a scraper is guaranteed, coating uniformity is remarkably improved, then a servo motor is controlled to rotate forwards and backwards, a worm is driven to rotate, the worm is meshed with a worm gear to drive a second rotating block to rotate, and the first rotating block and the second rotating block are linked through a rigid connecting plate to guarantee synchronous rotation of the first rotating block and the second rotating block. And angle deviation is avoided.

The invention discloses a preparation method of an epinephrine substance-loaded silk fibroin microneedle transdermal patch, which comprises the following steps: dissolving aminophenylboronic acid in a dimethyl sulfoxide aqueous solution to obtain an aminophenylboronic acid solution; adding the aminophenylboronic acid solution into a silk fibroin aqueous solution, then adding 1-ethyl-(3-dimethylaminopropyl) carbodiimide hydrochloride and N-hydroxysuccinimide, and uniformly mixing to obtain a reaction solution; after the reaction of the reaction solution is finished, dialyzing to remove the small molecule catalyst and dimethyl sulfoxide to obtain a first mixed solution; the method comprises the following steps: dissolving an epinephrine substance in deionized water to obtain an epinephrine substance solution; adding the epinephrine substance solution into the first mixed solution, and uniformly mixing to obtain a second mixed solution; and casting the second mixed solution into a microneedle mold, defoaming, and drying to obtain the adrenaline substance-loaded silk fibroin microneedle transdermal patch.

The invention provides a dexmedetomidine transdermal patch which comprises a backing layer, a release film and a polymer matrix layer arranged between the backing layer and the release film, the polymer matrix layer comprises dexmedetomidine, povidone and a pressure-sensitive adhesive, based on the total mass of the polymer matrix layer, the dexmedetomidine accounts for 4-10%, the povidone accounts for 5-10%, and the pressure-sensitive adhesive accounts for 5-10%. The povidone accounts for 2-12%, and the pressure-sensitive adhesive accounts for 78-94%; the pressure-sensitive adhesive comprises at least one of polymers containing carboxyl or hydroxyl functionalization.

The present invention provides a transdermal patch suitable for releasing an active ingredient having a large molecular weight. A transdermal patch 10 according to the present invention is provided with a substrate 1 and a retaining layer 2 that retains an active ingredient. The active ingredient contains an organic compound C having a weight-average molecular weight of 1,000 or more. The retaining layer 2 contains a porous filler. In another aspect, the present invention provides a transdermal patch 11 provided with a substrate 1, a retaining layer 2 that retains an active ingredient, and an adhesive layer 3 in this order in the stacking direction, wherein: the active ingredient contains an organic compound C having a weight-average molecular weight of 1000 or more; and at least one layer selected from the group consisting of the retaining layer 2 and the adhesive layer 3 contains a porous filler.

Systems, computer programs, devices, and methods that enable coordination across multiple devices of the mobile ecosystem. In one embodiment, smart glasses detect when a user is about to eat food or take a drink and capture the consumable and portion. The data is recorded in a “morsel track” for health activity analysis. Low-fidelity captures provide preliminary recognition, while higher-fidelity captures are selectively invoked for definitive classification. Machine-learning logic generates predicted metabolic responses, such as real-time glucose trends, based on the recorded events. Predicted responses may dynamically adjust the operation of continuous glucose monitors, heart-rate sensors, or other biomedical devices. In some embodiments, the system triggers a pharmaceutical dispenser, such as an insulin pump, inhaler, or transdermal patch, to provide closed-loop therapeutic intervention in real time.

The invention discloses a sustained and controlled release transdermal patch and a preparation process thereof, and particularly relates to the technical field of pharmaceutical preparations, the patch is of a five-layer composite structure, and the patch is characterized in that an adhesive layer and a drug storage layer both contain ion pairs formed by clonidine and organic acid in situ under specific solvent and temperature conditions; the formation of the composition is confirmed through a pH value or an infrared spectrum, then a specific percutaneous penetration enhancer is compounded, and programmed controlled release is realized through double-layer synergy. The preparation process adopts a sequence of firstly forming ion pairs and then mixing, the coating precision of + / -2 microns is realized by matching slit extrusion coating with on-line thickness measurement closed-loop control, and real-time quality control is performed by adopting a gradient drying process with clear temperature zone, wind speed and humidity parameters and on-line near infrared spectrum detection based on a pre-established PLS regression model. The process disclosed by the invention can ensure that the patch realizes near-zero-level constant-speed release within 168 hours, and has the advantages of stable drug release, uniform content, stable quality and high inter-batch consistency.

The objective is to provide a patch support in which strong adhesion between the two main surfaces is prevented, thereby enabling the efficient manufacture of patches. [Solution] The adhesive patch support according to the present invention comprises a film laminate formed by laminating a first film layer containing a polyester resin and a second film layer containing a resin with a lower glass transition temperature than the polyester resin. In addition, the main surface of the second film layer exposed in the adhesive patch support is characterized by having an uneven structure. This configuration prevents the two main surfaces of the adhesive patch support according to the present invention from adhering strongly to each other.

The invention provides a compound estradiol-progesterone transdermal patch and a preparation method thereof, and belongs to the technical field of medicines. The compound estradiol-progesterone transdermal patch provided by the invention comprises a backing layer, a drug-containing pressure-sensitive adhesive layer and a protective layer, and the drug-containing pressure-sensitive adhesive layer is located between the backing layer and the protective layer; the drug-containing pressure-sensitive adhesive layer comprises estradiol, progesterone, a penetration enhancer, a plasticizer, an antioxidant and a pressure-sensitive adhesive. The compound estradiol-progesterone transdermal patch provided by the invention is good in formability and adhesiveness, and a transdermal penetration test and pharmacokinetics show that the compound estradiol-progesterone transdermal patch provided by the invention is good in transdermal performance, and has an obvious slow release characteristic in in-vivo and in-vitro drug release.

A transdermal sustained-release patch for buspirone hydrochloride comprises a polyester film carrier as the backing layer, a pressure-sensitive adhesive reservoir layer prepared on the surface of the backing layer, and finally covered with a polyethylene protective film to obtain the sustained-release patch. The pressure-sensitive adhesive reservoir layer consists of a drug solution layer and an adhesive layer matrix. The drug solution layer is composed of buspirone hydrochloride, triethylamine, and glycerin, while the adhesive layer matrix is ​​composed of polyacrylate, triethylamine, a penetration enhancer, and glycerin. This invention's transdermal sustained-release patch for buspirone hydrochloride achieves a transdermal bioavailability of over 60% within 24 hours. A dose of 1.5 mg / patch achieves the equivalent effect of 10 mg orally, reducing the dosing frequency from 2-3 times daily to once daily, significantly improving patient compliance. The patch's pH value is controlled at 7.2-7.5, resulting in low skin irritation (HRIPT score ≤1.0). The process is simple, requiring no added sustained-release materials, only standard transdermal patch excipients, making production straightforward.

The invention relates to a bisoprolol long-acting transdermal absorption patch, and belongs to the technical field of medicines. The percutaneous absorption patch disclosed by the invention is suitable for being applied for three days, and consists of a backing layer, a medicine-carrying pressure-sensitive adhesive layer and an anti-sticking layer. The drug-loading pressure-sensitive adhesive layer comprises a bisoprolol organic acid ion pair compound, a pressure-sensitive adhesive and a percutaneous absorption enhancer. Wherein the weight of the bisoprolol organic acid ion pair compound accounts for 5-45wt% of the total weight of the medicine-carrying pressure-sensitive adhesive layer, the weight of the pressure-sensitive adhesive accounts for 50-90wt% of the total weight of the pressure-sensitive adhesive layer, and the dosage of the percutaneous absorption enhancer accounts for 1-20wt% of the total weight of the pressure-sensitive adhesive layer. Wherein in the bisoprolol organic acid ion pair compound, the molar ratio of bisoprolol free alkali to different organic acids is (0.5: 1)-(2: 1). The patch is simple in preparation technology and low in cost, realizes constant-speed drug release, provides a continuous treatment effect of at least three days, and is beneficial to control of symptoms and disease progression; and the method is safe, effective, good in stability and convenient to use.